All In Biotech

Drug Trial Radar · NCT06013865

Empagliflozin Treatment in Kidney Transplant Recipients

An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Apr 5, 2024

Primary completion

Mar 31, 2030

Study completion Mar 31, 2030

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
Iowa City VA Health Care System; VA Pittsburgh Healthcare System; VA Tennessee Valley Health Care System; VA Hines Health Care
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.

Conditions

  • Kidney Transplant
  • Chronic Kidney Disease

Interventions

  • EmpagliflozinDrug

    SGLT2 Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Discontinuation of EmpagliflozinTime frame: about 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Edward Hines Jr. VA Hospital, Hines, IL

    Hines, Illinois · Recruiting

  • Iowa City VA Health Care System, Iowa City, IA

    Iowa City, Iowa · Recruiting

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

    Omaha, Nebraska · Recruiting

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    Pittsburgh, Pennsylvania · Recruiting

  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TN

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.